Previous 10 | Next 10 |
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 Earnings Conference Call November 10, 2021, 8:30 AM ET Company Participants Patrick McEnany – Chairman and Chief Executive Officer Ali Grande – CFO Steven Miller – Chief Operating Officer and Chief Scientific Officer Jeffrey Del Ca...
Catalyst Pharmaceuticals (NASDAQ:CPRX): Q3 Non-GAAP EPS of $0.14 beats by $0.04; GAAP EPS of $0.10 in-line. Revenue of $35.95M (+22.6% Y/Y) beats by $1.54M. Press Release Cash and Investments were approximately $174.8 million as of September 30, 2021. For further details see: Catalyst P...
Continued Strong Financial and Operational Performance in the Third Quarter 2021 FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020 Plans to Seek to Expand the U.S. Approval of FIRDAPSE To Include Pediatric LEMS Patients Strong Cash Po...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many investors love to invest in lower-priced stocks as they can offer higher potential for gains. Low-priced stocks typically don’t get the attention they deserve by the greater investment community. But that does...
Today, we put the spotlight on Catalyst Pharmaceuticals for the first time. The company has one product FIRDAPSE on the market and has seen some positive news flow as well as analyst commentary in recent months. A full investment analysis follows in the paragraphs below. For...
CORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with r...
The smaller cap biotech space offers two key advantages for investors right now: cyclical diversification and diversification away from the vaccine monolithic theme. To break that down a bit, the stock market has been volatile over the past month, with many growth plays getting smacked down a...
The following slide deck was published by Catalyst Pharmaceuticals, Inc. in conjunction with this event. For further details see: Catalyst Pharmaceuticals (CPRX) Presents At 2021 Cantor Virtual Global Healthcare Conference
CORAL GABLES, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare ...
CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare ...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...